Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 4 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.


Player Avatar SmartEquity (40.32) Submitted: 1/21/2013 9:08:25 AM : Outperform Start Price: $8.63 AMRN Score: -124.16

The market is discounting the commercialization potential of its star drug and not accounitng for the excellent team behind this launch.

Featured Broker Partners